Main roads to melanoma G Palmieri, M Capone, ML Ascierto, G Gentilcore, DF Stroncek, M Casula, ... Journal of translational medicine 7, 1-17, 2009 | 249 | 2009 |
A signature of immune function genes associated with recurrence-free survival in breast cancer patients ML Ascierto, M Kmieciak, MO Idowu, R Manjili, Y Zhao, M Grimes, ... Breast cancer research and treatment 131, 871-880, 2012 | 184 | 2012 |
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce HM Kluger, HA Tawbi, ML Ascierto, M Bowden, MK Callahan, E Cha, ... Journal for immunotherapy of cancer 8 (1), 2020 | 179 | 2020 |
The intratumoral balance between metabolic and immunologic gene expression is associated with anti–PD-1 response in patients with renal cell carcinoma ML Ascierto, TL McMiller, AE Berger, L Danilova, RA Anders, GJ Netto, ... Cancer immunology research 4 (9), 726-733, 2016 | 171 | 2016 |
CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2 D Bedognetti, TL Spivey, Y Zhao, L Uccellini, S Tomei, ME Dudley, ... British journal of cancer 109 (9), 2412-2423, 2013 | 150 | 2013 |
Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma Q Xie, R Bradley, L Kang, J Koeman, ML Ascierto, A Worschech, ... Proceedings of the National Academy of Sciences 109 (2), 570-575, 2012 | 147 | 2012 |
Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients ML Ascierto, MO Idowu, Y Zhao, H Khalak, KK Payne, XY Wang, ... Journal of translational medicine 11, 1-11, 2013 | 117 | 2013 |
Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon‐mediated rejection genes R Carretero, E Wang, AI Rodriguez, J Reinboth, ML Ascierto, AM Engle, ... International journal of cancer 131 (2), 387-395, 2012 | 107 | 2012 |
Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis TL Spivey, L Uccellini, ML Ascierto, G Zoppoli, V De Giorgi, LG Delogu, ... Journal of translational medicine 9, 1-22, 2011 | 104 | 2011 |
An immunologic portrait of cancer ML Ascierto, VD Giorgi, Q Liu, D Bedognetti, TL Spivey, D Murtas, ... Journal of translational medicine 9, 1-13, 2011 | 103 | 2011 |
Transcriptional mechanisms of resistance to anti–PD-1 therapy ML Ascierto, A Makohon-Moore, EJ Lipson, JM Taube, TL McMiller, ... Clinical cancer research 23 (12), 3168-3180, 2017 | 82 | 2017 |
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop D Bedognetti, M Ceccarelli, L Galluzzi, R Lu, K Palucka, J Samayoa, ... Journal for immunotherapy of cancer 7, 1-23, 2019 | 80 | 2019 |
Association of HIV status with local immune response to anal squamous cell carcinoma: implications for immunotherapy EL Yanik, GJ Kaunitz, TR Cottrell, F Succaria, TL McMiller, ML Ascierto, ... JAMA oncology 3 (7), 974-978, 2017 | 73 | 2017 |
IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes D Murtas, D Maric, V De Giorgi, J Reinboth, A Worschech, P Fetsch, ... British journal of cancer 109 (1), 76-82, 2013 | 66 | 2013 |
Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and … N Pore, S Wu, N Standifer, M Jure-Kunkel, M de Los Reyes, Y Shrestha, ... Cancer Discovery 11 (11), 2828-2845, 2021 | 60 | 2021 |
TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness J Shan, SP DSouza, S Bakhru, EK Al-Azwani, ML Ascierto, KS Sastry, ... Cancer research 73 (9), 2840-2849, 2013 | 52 | 2013 |
Melanoma NOS1 expression promotes dysfunctional IFN signaling Q Liu, S Tomei, ML Ascierto, V De Giorgi, D Bedognetti, C Dai, L Uccellini, ... The Journal of clinical investigation 124 (5), 2147-2159, 2014 | 51 | 2014 |
Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by … F Marras, A Casabianca, F Bozzano, ML Ascierto, C Orlandi, A Di Biagio, ... Journal of virology 91 (23), 10.1128/jvi. 00647-17, 2017 | 47 | 2017 |
Distinct signatures of the immune responses in low risk versus high risk neuroblastoma M Gowda, K Godder, M Kmieciak, A Worschech, ML Ascierto, E Wang, ... Journal of Translational Medicine 9, 1-8, 2011 | 47 | 2011 |
Th17 immune microenvironment in Epstein-Barr virus–negative Hodgkin lymphoma: Implications for immunotherapy AS Duffield, ML Ascierto, RA Anders, JM Taube, AK Meeker, S Chen, ... Blood advances 1 (17), 1324-1334, 2017 | 46 | 2017 |